ResMed | vs Smith & Nephew
Smith & Nephew reported revenue of $6.2 billion in fiscal 2025, about the same as ResMed |'s $5.7 billion in fiscal 2026. ResMed |'s revenue grew 9.8% in its latest year, and Smith & Nephew's grew 6.1%. ResMed | had an operating margin of 33.4%, against 12.9% at Smith & Nephew. Free cash flow was $1.6 billion at ResMed | and $852 million at Smith & Nephew. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.
Side by side
| ResMed | | Smith & Nephew | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $5.7B | $6.2B |
| Revenue growth | 9.8% | 6.1% |
| Revenue growth a year, last 5 years | 12.1% | 6.2% |
| Gross margin | 61.1% | 68.0% |
| Operating margin | 33.4% | 12.9% |
| Net margin | 26.9% | 10.1% |
| Free cash flow | $1.6B | $852M |
| Free cash flow margin | 29.2% | 13.8% |
| Return on capital | 26.7% | — |
| Net debt to EBITDA | −0.4x | — |
| Dividends and buybacks | $1.0B | $832M |
| Change in diluted share count | −0.9% | −0.3% |
| Last close | $253.20 | $30.47 |
| P/E at the last close | 24.3× | — |
| Insider trades, last 12 months | sold $22.4 million | — |
| Piotroski F-score | 6 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ResMed |Smith & Nephew
Operating margin
Percent of revenue
ResMed |Smith & Nephew
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ResMed |Smith & Nephew
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ResMed | and Smith & Nephew pages.